Eric Keller
Amministratore Delegato presso Response Pharmaceuticals, Inc.
Profilo
Eric Keller is the founder of Response Pharmaceuticals, Inc. He currently holds a Director position at Noveome Biotherapeutics, Inc.
Posizioni attive di Eric Keller
| Società | Posizione | Inizio |
|---|---|---|
Noveome Biotherapeutics, Inc.
 Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Direttore/Membro del Consiglio | 16/11/2022 |
Response Pharmaceuticals, Inc.
 Response Pharmaceuticals, Inc. BiotechnologyHealth Technology Response Pharmaceuticals, Inc. is a clinical-stage therapeutic development company that focuses on developing treatments for weight management and metabolic disease. The company is based in Falls Church, VA. The company's initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. The company was founded by Eric Keller, Paul Sweetnam. Eric Keller has been the CEO since incorporation. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Health Technology |
Response Pharmaceuticals, Inc.
Response Pharmaceuticals, Inc. BiotechnologyHealth Technology Response Pharmaceuticals, Inc. is a clinical-stage therapeutic development company that focuses on developing treatments for weight management and metabolic disease. The company is based in Falls Church, VA. The company's initial clinical focus is to help people taking antipsychotic medications for disabling mental illness combat weight gain and metabolic dysregulation that is endemic with these treatments. Response is developing RDX-002 as an adjunctive therapy for patients taking first-line antipsychotic therapy. The company was founded by Eric Keller, Paul Sweetnam. Eric Keller has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Eric Keller
